Standard advice often suggests waiting for disease progression before escalating therapy. In interstitial lung disease, delay usually narrows the window for benefit. I outline a practical, India-specific view of ILD treatment that balances evidence, safety, and access. The aim is simple. Help clinicians and informed patients make steady, defensible choices that preserve function and quality of life.

Current Medical Treatment Options for ILD in India

1. Antifibrotic Medications: Pirfenidone and Nintedanib

Antifibrotics remain the backbone for progressive fibrosing phenotypes, particularly idiopathic pulmonary fibrosis. As Clinical Trials Arena reports, pirfenidone and nintedanib hold FDA approval for IPF and are under study in non-IPF fibrosing ILDs. That regulatory history matters because it anchors payer decisions and sets expectations for monitoring.

In practice, I consider these agents when there is radiological fibrosis with progression, or when the clinical trajectory suggests likely decline. Early initiation helps, especially when baseline lung function is still respectable. The goal is not reversal. It is slowing forced vital capacity loss and stabilising symptoms to the extent possible.

Choice between the two is typically pragmatic. Tolerability, comorbidities, drug interactions, and dosing style shape adherence. I frame discussions around three questions.

• Which adverse effects are most likely for this patient, and how manageable are they.

• How often can we monitor liver enzymes and weight, realistically.

• What does insurance or a government scheme actually cover.

Aspect	Pirfenidone vs Nintedanib
Primary aim	Slow fibrosis progression and preserve function
Dosing considerations	Pirfenidone uses titration and multiple daily doses. Nintedanib uses fixed twice daily dosing.
Common issues	Pirfenidone: gastrointestinal upset and photosensitivity. Nintedanib: diarrhoea and liver enzyme elevation.
Monitoring	Liver function tests, weight, symptom diary, and adherence checks
When I reassess	Intolerable toxicity, clear progression despite adherence, or new comorbidity

Many patients ask how long ILD treatment should continue. The honest answer is until disease behaviour clarifies. If stability holds with acceptable safety, I continue. If the disease accelerates, I consider a switch or add supportive measures more aggressively.

2. Corticosteroids and Immunosuppressive Therapy

Steroids and steroid-sparing agents have a defined role in inflammatory ILD, including connective tissue disease associated disease, hypersensitivity pneumonitis with active inflammation, and certain vasculitides. For fibrotic, traction-dominant patterns without inflammation, benefit is limited and risks accumulate. I apply a tight framework.

• Confirm inflammatory activity with imaging, serology, or bronchoalveolar data where feasible.

• Use the lowest effective steroid dose, and taper on a clock, not habit.

• Introduce a steroid-sparing agent early for chronic indications.

My commonly considered steroid-sparing options include mycophenolate, azathioprine, and in selected connective tissue disease settings, rituximab or cyclophosphamide. Drug selection maps to autoantibody profile, fertility considerations, infection risk, and service capacity for monitoring. Precision beats broad escalation. Always.

3. Newer Medications: Nerandomilast and Treprostinil

Nerandomilast has emerged as a third line of defence for idiopathic pulmonary fibrosis. In a development that widened the therapeutic field after a long gap, Nature reported FDA approval, with trials showing slower decline in forced vital capacity. Mechanistically, the PDE4 pathway focus offers an anti inflammatory route that may complement antifibrotics.

Treprostinil belongs in a different niche. Inhaled treprostinil targets pulmonary hypertension secondary to interstitial lung disease, and it aims to improve functional capacity. The pivotal study showed a meaningful increase in six minute walk distance versus placebo, as detailed in NEJM. When I see disproportionate breathlessness and echo evidence of pulmonary hypertension, I evaluate for this pathway, with shared decision making around device use and follow up.

These agents are not universal answers. They fit defined phenotypes and require disciplined follow up. The pattern is clear. Better phenotyping yields sharper outcomes.

4. Stem Cell Therapy Options

Stem cell offers appear in clinics and online brochures, often with confident language. Rigorous evidence for stem cell therapy in fibrosing ILD is limited, and regulatory frameworks remain cautious. I advise against commercial stem cell interventions outside a registered clinical trial with transparent protocols and ethics board oversight. If a patient asks, I review the proposed cell source, delivery route, regulatory status, and monitoring plan. Most offers do not pass that basic scrutiny.

Put plainly, hope is not a plan. Proven ILD treatment and structured rehabilitation outperform speculative injections in real life settings.

5. Combination Therapy Approaches

Combination therapy can mean two different things in this area. First, antifibrotics alongside immunosuppression for connective tissue disease associated ILD when both fibrosis and inflammation drive morbidity. Second, antifibrotics with novel agents in research settings, where distinct biological pathways are targeted in parallel. The former is already common in tertiary centres. The latter remains in trials and selected expanded access programs.

My operational rules are conservative. Start one change at a time, establish tolerance, then add the second agent if the phenotype warrants it. Document baseline liver function and gastrointestinal status, and agree upfront triggers for dose reduction or discontinuation. Precision reduces avoidable harm.

Diagnostic Procedures and Monitoring

High-Resolution CT Scan Requirements

High resolution CT is the cornerstone for pattern recognition. I request thin slices, volumetric acquisition, prone views if artefact is suspected, and expiratory views if small airway disease is possible. The aim is accurate pattern labelling: UIP, probable UIP, NSIP, or an unclassifiable fibrosing pattern. A robust CT protocol reduces biopsy need and prevents misclassification.

For serial monitoring, I prefer consistent scanners and protocols across time. Variation in reconstruction kernels can mimic change. That is an avoidable error.

Pulmonary Function Tests

PFTs track physiology when symptoms can mislead. I anchor on FVC and DLCO trends, with quality control notes attached. A single value rarely decides management. A series, interpreted with context, often does. If cough worsens but FVC is stable, I search for reflux or airway hyperresponsiveness. If DLCO falls disproportionately, I screen for pulmonary hypertension or anaemia.

• Baseline: spirometry, lung volumes when possible, and DLCO.

• Follow up: repeat at fixed intervals, aligning with clinic visits.

• Interpretation: compare percent predicted values and absolute change.

Six-Minute Walk Test

The six minute walk test offers a functional lens that patients understand. I use standardised corridors, continuous oximetry, and a pre planned turning protocol. The metrics matter. Distance covered, nadir oxygen saturation, and recovery profile provide complementary insights. When therapy aims to improve exercise capacity, this test is the practical readout.

Results drive oxygen therapy planning, rehabilitation intensity, and in pulmonary hypertension, drug escalation discussions. It is simple. It is reproducible when done well.

Bronchoscopy and Lung Biopsy

Bronchoscopy helps when infection, eosinophilia, or alveolar haemorrhage is suspected. I reserve it for questions that change management. For biopsies, the calculus is stricter. I discuss risks, centre experience, and whether a confident CT pattern makes tissue unnecessary. Transbronchial cryobiopsy has improved yield in experienced hands, but it still belongs in centres with protocols and multidisciplinary teams.

When multidisciplinary discussion answers the diagnostic question without tissue, I do not add risk to satisfy curiosity. Diagnosis is a team sport in this field.

Blood Tests and Biomarkers

Serology screens for connective tissue disease and hypersensitivity. I prioritise ANA profile, rheumatoid factor, CCP, myositis panels, and precipitins where exposures are plausible. Biomarkers beyond serology remain exploratory. If a biomarker cannot change therapy this year, I avoid ordering it this year. Resource stewardship matters in routine ILD treatment.

Supportive Care and Rehabilitation

Oxygen Therapy Criteria and Implementation

Oxygen use should be systematic, not symbolic. I look for resting hypoxaemia, significant desaturation on exertion, or nocturnal hypoxia on appropriate studies. If targets are not met during a controlled walk, I trial ambulatory oxygen with titration to symptom relief and acceptable saturation. The setup includes device choice, cannula comfort, and safety training at home.

• Assess: resting, exertional, and nocturnal oxygen needs.

• Prescribe: flow rates for rest and activity, with clear written targets.

• Review: adherence, skin care, and fall risks related to tubing.

Pulmonary Rehabilitation Programs

Structured rehabilitation is a potent intervention with few downsides. Programmes combine endurance training, strength work, breathing techniques, and education on pacing. I advocate enrolment soon after diagnosis of a fibrosing phenotype. Patients often report improved confidence and reduced dyspnoea, even when spirometry is unchanged.

Rehabilitation also builds a platform for safer escalation of pharmacotherapy. Fitness is a therapy multiplier.

Exercise Training Benefits

Exercise training improves functional capacity and quality of life. Gains appear in walking distance and patient reported breathlessness. My approach is moderate intensity, interval based work with supervision early on. Resistance training protects against deconditioning and helps with daily tasks like stair climbing or carrying groceries.

• Endurance: intervals at tolerable intensity, twice weekly at minimum.

• Strength: large muscle groups, low to moderate load, controlled form.

• Breathing: pursed lip and diaphragmatic training, integrated into exercise.

Lifestyle Modifications

Small changes compound. Smoke exposure must stop, including biomass fuels at home. Reflux control reduces cough burden for many, so I use diet adjustments, head end elevation, and medication when indicated. Sleep hygiene, vaccinations, and infection control practices lower exacerbation risk. A written plan beats vague advice here.

Vaccination Recommendations

Vaccination protects vulnerable lungs. I recommend influenza vaccination annually and pneumococcal vaccination as per age and risk status. When immunosuppression is planned, I check varicella and hepatitis serology and update non live vaccines before therapy. Live vaccines require timing discussions to avoid unsafe windows. Clear records prevent confusion later.

Treatment Costs and Healthcare Access in India

Medication Costs: Antifibrotics Comparison

Costs vary by brand, state tenders, and insurance arrangements. When discussing antifibrotics, I map a month by month budget that includes drug, lab monitoring, and clinic reviews. Generic availability can reduce expense, but quality and supply stability must be considered. Patient assistance programmes from manufacturers or hospitals can bridge gaps. For many families, predictability matters as much as headline price.

• Request written quotations from two pharmacies for sustained therapy.

• Confirm refill cycles and stock reliability before committing.

• Factor transport and time costs for frequent monitoring visits.

Hospitalisation Expenses

Hospitalisation drivers include acute exacerbations, infections, and procedures such as bronchoscopy or cryobiopsy. Costs reflect length of stay, level of care, antibiotics, oxygen modality, and procedure fees. To reduce financial shock, I prepare an escalation plan with clear thresholds for admission. Many admissions are preventable with earlier antibiotics, home oxygen adaptation, or day care infusions where appropriate.

Insurance Coverage Options

Coverage depends on policy wording and pre existing disease clauses. I encourage a policy review with the insurer for clarity on antifibrotics, pulmonary rehabilitation, home oxygen, and non invasive ventilation if needed. For new policies, waiting periods and sub limits can cause surprises. Documentation of medical necessity and standard of care improves claim success. Precision in paperwork helps patients as much as prescriptions.

Government Schemes and Support

Several state and central schemes support chronic disease care. Eligibility often ties to income certificates, disability assessments, or specific hospitals. Social workers in tertiary centres usually know the latest operational rules. I advise patients to secure essential identity documents and a consolidated medical summary early. Prepared families access support faster.

Regional Treatment Centres

Specialised ILD clinics exist in major metros and selected regional hubs. Capacity varies by centre. When distance is a barrier, I set a hybrid plan: periodic in person reviews at a referral centre and local follow up for labs and spirometry. That split model preserves quality and reduces travel fatigue. Good coordination is the difference between a plan on paper and a plan that works.

Making Informed Treatment Decisions

ILD treatment is not a single decision. It is a sequence of small, linked choices. I use a simple framework that keeps decisions disciplined and transparent.

1. Phenotype clearly. HRCT pattern, autoantibodies, exposure history, and physiology trends.

2. Prioritise objectives. Slow fibrosis, reduce inflammation, improve function, or palliate symptoms.

3. Select the least complex option that achieves today’s objective. Reassess in a fixed interval.

4. Plan monitoring and support. Tests, rehab, oxygen, and safety netting.

5. Review affordability and access before finalising a prescription.

Conflicts will arise. Patients value energy for family events, not only percentages on a chart. I respect those trade offs. And yet, I keep momentum with modest, timely changes. Small wins accumulate and protect independence.

A short example helps. A 62 year old with idiopathic pulmonary fibrosis, stable FVC but worsening walks. I continue antifibrotic therapy, intensify rehabilitation, screen for pulmonary hypertension, and address reflux. No drama. Just steady ILD treatment anchored to objective measures and the patient’s goals.

Frequently Asked Questions

What is the monthly cost of pirfenidone and nintedanib in India?

Prices differ by manufacturer, state, and procurement route. Hospital pharmacies, empanelled schemes, and patient assistance programmes can substantially change out of pocket expense. I recommend obtaining written quotes from two suppliers and confirming refill reliability. Consider the full monthly budget, including lab monitoring and clinic visits, not only tablets.

Can ILD be completely cured with current treatments?

Fibrosing disease is generally not curable. Current options slow decline, stabilise symptoms, and extend functional independence. In inflammatory ILD, remission is possible with steroids and immunosuppressants, though relapses occur. I frame goals around slowing progression, reducing exacerbations, and preserving quality of life.

When should oxygen therapy be started for ILD patients?

I consider oxygen when resting saturation is low, when exertional desaturation appears on a standard walk test, or when nocturnal hypoxia is documented. Prescription includes rest and activity flow rates with clear targets. The plan should also cover device choice, safety, and structured follow up to confirm benefit.

Which hospitals offer specialised ILD treatment in India?

Tertiary centres in major metros usually host multidisciplinary ILD clinics. Several regional medical colleges now run dedicated services as well. Selection criteria include access to high quality HRCT, experienced pulmonologists, rheumatology support, interventional bronchoscopy, and rehabilitation programmes. Proximity matters, but experience matters more.

What are the side effects of antifibrotic medications?

Pirfenidone commonly causes gastrointestinal upset and photosensitivity. Nintedanib often leads to diarrhoea and liver enzyme elevations. I mitigate issues with slow titration, sun protection, antidiarrhoeals when needed, and regular liver function tests. Most side effects are manageable with early reporting and dose adjustments.

Is lung transplant available for ILD patients in India?

Yes, in selected centres with established transplant programmes. Candidacy depends on age, comorbidities, social support, and disease trajectory. Referral should occur before severe deconditioning. Transplant is not a rescue for late stage instability. It is a planned transition with strict criteria.

How often should lung function tests be performed?

For stable disease on treatment, I repeat spirometry and DLCO at defined intervals, typically several months apart. Faster intervals apply when starting new therapy, facing potential progression, or preparing for transplant referral. Align testing with clinic visits to support decisions and reduce extra travel.